Categorization of Non-Hodgkin’s Hematosarcomas (Lymphomas) According to T- and B-Cell Markers: Its Value for Diagnosis and Prognosis

1978 ◽  
pp. 146-157
Author(s):  
D. Belpomme ◽  
B. Caillou ◽  
N. Lelarge ◽  
I. Botto ◽  
E. Pujade Lauraine ◽  
...  
Keyword(s):  
B Cell ◽  
Cell Markers ◽  
Diagnosis And Prognosis

A Challenging Case of A Myeloid Sarcoma Misdiagnosed as High Grade B-Cell Lymphoma

2020 ◽  
Vol 154 (Supplement_1) ◽  
pp. S97-S97
Author(s):  
A Herrmann ◽  
B Mai ◽  
S Elzamly ◽  
A Wahed ◽  
A Nguyen ◽  
...  
Keyword(s):  
Bone Marrow ◽  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Myeloid Sarcoma ◽  
Proliferation Index ◽  
High Grade ◽  
Cell Markers ◽  
Thoracolumbar Region ◽  
The Right

Abstract Introduction/Objective A 46-year-old female presented with severe back pain associated with progressive bilateral lower extremity weakness and paresthesia, urinary retention, and constipation. Computed tomography revealed a retroperitoneal mass encasing the right psoas muscle, obstructing the right kidney, and extending to the thoracolumbar region resulting in severe spinal compression. An epidural tumor resection was subsequently performed at an outside hospital. Methods Histological sections showed sheets of blastoid neoplastic cells with intermediate to large nuclei, irregular membranes, fine chromatin, and prominent nucleoli. Immunohistochemical stains showed that these cells were positive for CD43, CD79a (weak, focal), BCL2, C-MYC, and PAX5 (weak, focal) and negative for CD10, CD20, CD30, ALK1, BCL6, MUM1, and Tdt. The Ki-67 proliferation index was 75-80%. With this immunophenotype, this patient was diagnosed with a high grade B-cell lymphoma and transferred to our institution for further work-up. On review of the slides, further immunohistochemical testing was requested which revealed positivity for CD117 and myeloperoxidase (MPO). Results The overall morphological and immunophenotypical features are most compatible with myeloid sarcoma (MS) with aberrant expression of B-cell markers and this patient’s diagnosis was amended. Interestingly, the patient’s bone marrow examination only showed 2% myeloblasts with left shifted granulocytosis and concurrent fluorescence in situ hybridization (FISH) studies were negative. Conclusion A literature review showed that 40-50% of MS are misdiagnosed as lymphoma. MS can frequently stain with B-cell or T-cell markers, as seen in this case, which makes it challenging for an accurate diagnosis and sub- classification. In addition, our case is interesting in that there was only extramedullary presentation without bone marrow involvement. Typically, MS develops after the diagnosis of acute myeloid leukemia (AML) with an incidence of 3–5% after AML. It can also manifest de novo in healthy patients, who then go on to develop AML months to years later. Therefore, this patient will require close follow-up.

scholarly journals CD5-positive chronic B-cell lymphoproliferative disorders: Diagnosis and prognosis of a heterogeneous disease entity

2010 ◽  
Vol 78B (S1) ◽  
pp. S35-S41 ◽  
Author(s):  
Roxana S. Dronca ◽  
Dragan Jevremovic ◽  
Curtis A. Hanson ◽  
Kari G. Rabe ◽  
Tait D. Shanafelt ◽  
...  
Keyword(s):  
B Cell ◽  
Lymphoproliferative Disorders ◽  
Disease Entity ◽  
Diagnosis And Prognosis

A1.12 B-cell markers expression is affected by TNF-inhibitors and tocilizumab treatment in rheumatoid arthritis

2015 ◽  
Vol 74 (Suppl 1) ◽  
pp. A5.2-A5
Author(s):  
RA Moura ◽  
C Quaresma ◽  
Ar Vieira ◽  
MJ Gonçalves ◽  
J Polido-Pereira ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
B Cell ◽  
Tnf Inhibitors ◽  
Cell Markers

scholarly journals Role of Immunohistochemistry in Staging Diffuse Large B-cell Lymphoma (DLBCL)

2008 ◽  
Vol 56 (10) ◽  
pp. 893-900 ◽  
Author(s):  
Dipti Talaulikar ◽  
Jane Esther Dahlstrom ◽  
Bruce Shadbolt ◽  
Amy Broomfield ◽  
Anne McDonald
Keyword(s):  
Bone Marrow ◽  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Cox Regression Analysis ◽  
Cell Markers ◽  
Large B Cell Lymphoma ◽  
Lymphomatous Involvement ◽  
The Impact ◽  
Large B Cell

The use of immunohistochemistry (IHC) in staging bone marrow in non-Hodgkin's lymphoma (NHL) is largely limited to ambiguous cases, particularly those with lymphoid aggregates. Its role in routine clinical practice remains unestablished. This study aimed to determine whether the routine use of IHC in diffuse large B-cell lymphoma (DLBCL) would improve the detection of lymphomatous involvement in the bone marrow. It also sought to determine the impact of IHC on predicting survival compared with routine histological diagnosis using hematoxylin and eosin (H&E), Giemsa, and reticulin staining. The bone marrow trephines of 156 histologically proven DLBCL cases were assessed on routine histology, and IHC using two T-cell markers (CD45RO and CD3), two B-cell markers (CD20 and CD79a), and κ and λ light chains. IHC detected lymphomatous involvement on an additional 11% cases compared with histology alone. Although both routine histology and IHC were good predictors of survival, IHC was better at predicting survival on stepwise multivariate Cox regression analysis. IHC performed routinely on bone marrow trephines has the ability to improve detection of occult lymphoma in experienced hands. Furthermore, it is a better predictor of survival compared with routine histological examination alone.

Expression of epstein-barr virus-encoded proteins and B-cell markers in fatal infectious mononucleosis

1990 ◽  
Vol 46 (6) ◽  
pp. 976-984 ◽  
Author(s):  
Kerstin Falk ◽  
Ingemar Ernberg ◽  
Ramasamy Sakthivel ◽  
Jack Davis ◽  
Birger Christensson ◽  
...  
Keyword(s):  
B Cell ◽  
Infectious Mononucleosis ◽  
Epstein Barr Virus ◽  
Cell Markers ◽  
Barr Virus ◽  
Encoded Proteins ◽  
Epstein Barr

Poor prognosis of children with acute lymphocytic leukemia and increased B cell markers

1976 ◽  
Vol 89 (6) ◽  
pp. 956-958 ◽  
Author(s):  
Lawrence J. Wolff ◽  
Susan T. Richardson ◽  
James B. Neiburger ◽  
Rochelle G. Neiburger ◽  
Deborah S. Irwin ◽  
...  
Keyword(s):  
B Cell ◽  
Poor Prognosis ◽  
Acute Lymphocytic Leukemia ◽  
Lymphocytic Leukemia ◽  
Cell Markers

scholarly journals Phenotypic heterogeneity in aneuploid multiple myeloma indicates pre-B cell involvement

Blood ◽  
1988 ◽  
Vol 71 (4) ◽  
pp. 861-865
Author(s):  
J Epstein ◽  
B Barlogie ◽  
J Katzmann ◽  
R Alexanian
Keyword(s):  
Multiple Myeloma ◽  
B Cell ◽  
Tumor Cells ◽  
Plasma Cell ◽  
Lymphoblastic Leukemia ◽  
Cell Markers ◽  
Aneuploid Tumor ◽  
Beta 2 Microglobulin ◽  
Normal Differentiation ◽  
Mature Plasma Cell

The expression of early and mature B cell markers, surface beta 2- microglobulin (B2M) and cytoplasmic immunoglobulin (clg) by aneuploid tumor cells in bone marrow aspirates from 44 patients with multiple myeloma was evaluated by correlated DNA immunofluorescence flow cytometry. Myeloma tumor cells of almost 90% of the patients contained monoclonal clg and expressed the mature plasma cell antigen R1–3 as well as surface B2M; common acute lymphoblastic leukemia antigen (CALLA) was present in 55%, B2 in 17%, and B4 in 23% of samples studied. Coexpression of CALLA and clg in 46% of all patients identified a novel myeloma phenotype without known counterpart in the normal differentiation of B cells. CALLA and clg were independently expressed and gave rise to CALLA+/clg-, CALLA+/clg+, and CALLA-/clg+ cells. The association of CALLA and mature plasma cell markers may define discrete stages of neoplastic plasma cell differentiation.

scholarly journals Tissue microarray: A valuable method in diagnosis and prognosis of hematological malignances

2005 ◽  
Vol 13 (3-4) ◽  
pp. 131-135 ◽  
Author(s):  
Goran Marjanovic ◽  
Stefan Dojcinov
Keyword(s):  
B Cell ◽  
Tissue Microarray ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Cost Effective ◽  
Lymphocytic Leukemia ◽  
Proliferation Index ◽  
Ki 67 ◽  
Diagnosis And Prognosis ◽  
Valuable Method

BACKGROUND: The novel technology of tissue microarray (TMA) allows rapid and cost-effective analysis of hundreds of markers on the same set of specimens. Limited amount of tissue that could be analyzed and problem of tissue heterogeneity, are the major drawbacks of TMA technique for immunohistochemical characterization of lymphomas. METHODS: In this paper 65 cases of lymphomas were analyzed using TMA with following panel of antibodies: BOB1, Oct2, Bcl2, Bcl6, CD20, CD21, CD23, CD3, CD5, CD10, CD43, CD79a, CD138, Cyclin D1, Ki67, MUM1, Pax5, p53. RESULTS: In 14 patients with diffuse large B-cell lymphoma (DLBCL), 5 were classified as germinative center and 3 as non-germinative center cases according to the Bcl6, CD10, and MUM1 positivity. Other 2 patients were identified as T cell rich B cell lymphoma based on morphology and Oct2 and BOB1 positivity of pleomorphic B lymphocytes. DLBCL with Bcl6+ immunophenotype had better overall survival than Bcl6- cases. All cases of classic mantle cell lymphoma had significantly lower Ki-67 proliferation index than blastoid subtypes. There were 14 cases of chronic lymphocytic leukemia/small cell lymphocytic lymphoma, 6 cases with follicular lymphoma, 5 cases of marginal zone lymphoma, and 7 cases of lymphoplazmacitoid lymphoma. In the indolent lymphoma group, survival of patients with p53+/- was poorer comparing to p53- group. CONCLUSION: We conclude that TMA technique is a valuable method in diagnosis and prognosis of lymphomas, which are considered very heterogeneous group of hematological neoplasms.

Sign in / Sign up

Export Citation Format

Share Document